<DOC>
	<DOC>NCT00002358</DOC>
	<brief_summary>To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.</brief_summary>
	<brief_title>A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV</brief_title>
	<detailed_description>Any physician qualified to treat pediatric AIDS patients may enroll patients in this study.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sorivudine</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV infection. Cutaneous, visceral, or ocular varicellazoster viral infection. Refractory or intolerant to acyclovir or foscarnet therapy. Consent of parent or guardian. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Inability to take oral capsules or tolerate liquids. Concurrent Medication: Excluded: 5flucytosine, 5fluorouracil, highdose prednisone, or probenecid. Patients with the following prior condition are excluded: History of immediate hypersensitivity to nucleoside analogues. Prior Medication: Excluded: 5flucytosine, 5fluorouracil, highdose prednisone, or probenecid within 4 weeks prior to study entry. Required: Prior acyclovir or foscarnet.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Herpes Zoster</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>sorivudine</keyword>
	<keyword>Chickenpox</keyword>
</DOC>